C-KIT Mutation Clinical Trial
Official title:
Dasatinib Combined With Multi-agents Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
In this multi-center, open-label, no control,prospective clinical trial, a total of 30 relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation patients will be enrolled. Dasatinib 70 mg twice a day will be administrated for two weeks from day 1 of re-induction chemotherapy. The purpose of current study is to determine the clinical efficacy and tolerability of combination therapy of dasatinib with multi-agent chemotherapy in relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02675478 -
Phase 1 Study of Quizartinib
|
Phase 1 | |
| Active, not recruiting |
NCT05226468 -
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
|
Phase 1 | |
| Terminated |
NCT03516760 -
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
|
Phase 1 |